Table 2 Anthropometric data during the intervention

From: Additive benefits of long-chain n-3 polyunsaturated fatty acids and weight-loss in the management of cardiovascular disease risk in overweight hyperinsulinaemic women

  WLFO (n=35) WLPO (n=32) Control (n=26) Time*Group
  Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks  
Weight (kg) 92.5 (15.0) 82.6 (14.3)*** 82.3 (14.6)*** 90.8 (15.0) 79.9 (14.6)*** 79.5 (15.1)*** 90.9 (16.5) 90.6 (17.0)†,‡‡ 91.2 (16.9)†,‡‡ <0.0001
Waist circumference (cm) 98.7 (11.1) 91.3 (11.9)*** 91.1 (11.3)*** 99.2 (11.6) 90.7 (13.3)*** 90.9 (13.1)*** 98.3 (10.8) 98.7 (11.2)††,‡‡ 99.3 (13.8)†,‡ <0.0001
BMI (kg/m2) 35.3 (5.6) 31.5 (5.2)*** 31.4 (5.4)*** 34.6 (5.3) 30.5 (5.3)*** 30.3 (5.6)*** 33.6 (5.7) 33.5 (5.8) 33.6 (5.9) <0.0001
DXA fat mass (kg) 43.1 (12.5) 33.5 (10.9)* 33.3 (11.1)* 42.5 (12.4) 32.2 (11.7)* 31.7 (12.3)* 40.9 (12.6) 40.6 (13.2)†,‡‡ 41.3 (13.5)†,‡‡ <0.0001
DXA abdominal fat (kg) 6.16 (2.55) 4.18 (2.10)*** 4.22 (2.11)*** 6.17 (3.09) 4.12 (2.62)*** 4.12 (2.73)*** 6.03 (2.82) 5.90 (2.80)††,‡ 6.12 (2.83)††,‡‡ <0.0001
  1. Data presented as geometric mean (s.d.) for all outcomes. Data analysed using random effects models of the change in outcome, adjusted for baseline values. Where significant time*group effects exist, * indicates significant differences within the group, vs baseline. Indicates significant differences vs the same timepoint in the WLFO group or vs the same timepoint in the WLPO group. Significance indicated by increasing number of symbols (*P<0.05, ***P<0.0001, P<0.05, ††P<0.01, ‡‡P<0.01, respectively).
  2. Abbreviations: BMI, body mass index; DXA, dual X-ray absorptiometry; WLFO, weight-loss programme, with LC n-3 PUFA. WLPO, weight-loss programme with placebo oil.